

# Adriana Balduzzi

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5209617/publications.pdf>

Version: 2024-02-01

70  
papers

7,437  
citations

147801  
31  
h-index

88630  
70  
g-index

73  
all docs

73  
docs citations

73  
times ranked

9496  
citing authors

#	ARTICLE	IF	CITATIONS
1	Tisagenlecleucel in Children and Young Adults with B-Cell Lymphoblastic Leukemia. New England Journal of Medicine, 2018, 378, 439-448.	27.0	3,680
2	Imatinib for refractory chronic graft-versus-host disease with fibrotic features. Blood, 2009, 114, 709-718.	1.4	210
3	Chronic graft-versus-host disease in children: incidence, risk factors, and impact on outcome. Blood, 2002, 100, 1192-1200.	1.4	201
4	Response to Rituximab-Based Therapy and Risk Factor Analysis in Epstein Barr Virus-Related Lymphoproliferative Disorder After Hematopoietic Stem Cell Transplant in Children and Adults: A Study From the Infectious Diseases Working Party of the European Group for Blood and Marrow Transplantation. Clinical Infectious Diseases, 2013, 57, 794-802.	5.8	196
5	Treatment of Graft versus Host Disease with Mesenchymal Stromal Cells: A Phase I Study on 40 Adult and Pediatric Patients. Biology of Blood and Marrow Transplantation, 2014, 20, 375-381.	2.0	181
6	Extracorporeal photochemotherapy for paediatric patients with graft-versus-host disease after haematopoietic stem cell transplantation. British Journal of Haematology, 2003, 122, 118-127.	2.5	174
7	Chemotherapy versus allogeneic transplantation for very-high-risk childhood acute lymphoblastic leukaemia in first complete remission: comparison by genetic randomisation in an international prospective study. Lancet, The, 2005, 366, 635-642.	13.7	167
8	Platelet-lysate-Expanded Mesenchymal Stromal Cells as a Salvage Therapy for Severe Resistant Graft-versus-Host Disease in a Pediatric Population. Biology of Blood and Marrow Transplantation, 2010, 16, 1293-1301.	2.0	165
9	Total Body Irradiation or Chemotherapy Conditioning in Childhood ALL: A Multinational, Randomized, Noninferiority Phase III Study. Journal of Clinical Oncology, 2021, 39, 295-307.	1.6	163
10	Results and factors influencing outcome after fully haploidentical hematopoietic stem cell transplantation in children with very high-risk acute lymphoblastic leukemia: impact of center size: an analysis on behalf of the Acute Leukemia and Pediatric Disease Working Parties of the European Blood and Marrow Transplant group. Blood, 2010, 115, 3437-3446.	1.4	159
11	Flash survey on severe acute respiratory syndrome coronavirus-2 infections in paediatric patients on anticancer treatment. European Journal of Cancer, 2020, 132, 11-16.	2.8	155
12	Extracorporeal Photochemotherapy Is Accompanied by Increasing Levels of Circulating CD4+CD25+GITR+Foxp3+CD62L+ Functional Regulatory T-Cells in Patients With Graft-Versus-Host Disease. Transplantation, 2007, 84, 31-39.	1.0	136
13	Interleukin-17-Producing T-Helper Cells as New Potential Player Mediating Graft-Versus-Host Disease in Patients Undergoing Allogeneic Stem-Cell Transplantation. Transplantation, 2009, 88, 1261-1272.	1.0	108
14	Lessons after the early management of the COVID-19 outbreak in a pediatric transplant and hemato-oncology center embedded within a COVID-19 dedicated hospital in Lombardia, Italy. Estote parati. Bone Marrow Transplantation, 2020, 55, 1900-1905.	2.4	104
15	Sleeping Beauty-engineered CAR T cells achieve antileukemic activity without severe toxicities. Journal of Clinical Investigation, 2020, 130, 6021-6033.	8.2	102
16	Unrelated donor vs HLA-haploidentical $\hat{1}\pm/\hat{1}^2$ T-cell- and B-cell-depleted HSCT in children with acute leukemia. Blood, 2018, 132, 2594-2607.	1.4	101
17	Front-line imatinib treatment in children and adolescents with chronic myeloid leukemia: results from a phase III trial. Leukemia, 2018, 32, 1657-1669.	7.2	86
18	Risk of complications during hematopoietic stem cell collection in pediatric sibling donors: a prospective European Group for Blood and Marrow Transplantation Pediatric Diseases Working Party study. Blood, 2012, 119, 2935-2942.	1.4	82

#	ARTICLE	IF	CITATIONS
19	Children with cancer in the time of COVID-19: An 8-week report from the six pediatric oncology centers in Lombardia, Italy. <i>Pediatric Blood and Cancer</i> , 2020, 67, e28410.	1.5	82
20	More precisely defining risk peri-HCT in pediatric ALL: pre- vs post-MRD measures, serial positivity, and risk modeling. <i>Blood Advances</i> , 2019, 3, 3393-3405.	5.2	81
21	Minimal residual disease before and after transplantation for childhood acute lymphoblastic leukaemia: is there any room for intervention?. <i>British Journal of Haematology</i> , 2014, 164, 396-408.	2.5	76
22	Regulatory T Cells and Extracorporeal Photochemotherapy: Correlation With Clinical Response and Decreased Frequency of Proinflammatory T Cells. <i>Transplantation</i> , 2009, 87, 1422-1425.	1.0	70
23	Extracorporeal Photochemotherapy for the Treatment of Chronic Graft-Versus-Host Disease: Trend for a Possible Cell Dose-Related Effect?. <i>Therapeutic Apheresis and Dialysis</i> , 2007, 11, 85-93.	0.9	61
24	Stem cell transplantation from HLA-matched related donor for Fanconi's anaemia: a retrospective review of the multicentric Italian experience on behalf of Associazione Italiana di Ematologia ed Oncologia Pediatrica (AIEOP)-Gruppo Italiano Trapianto di Mid. <i>British Journal of Haematology</i> , 2001, 112, 796-805.	2.5	56
25	Outcome of relapse after allogeneic HSCT in children with ALL enrolled in the ALL-SCT 2003/2007 trial. <i>British Journal of Haematology</i> , 2018, 180, 82-89.	2.5	50
26	Phase II Study of Sequential Infusion of Donor Lymphocyte Infusion and Cytokine-Induced Killer Cells for Patients Relapsed after Allogeneic Hematopoietic Stem Cell Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2017, 23, 2070-2078.	2.0	48
27	No difference in outcome between children and adolescents transplanted for acute lymphoblastic leukemia in second remission. <i>Blood</i> , 2011, 118, 6683-6690.	1.4	45
28	Nutritional Status in Untreated Children with Acute Leukemia as Compared with Children without Malignancy. <i>Journal of Pediatric Gastroenterology and Nutrition</i> , 1996, 23, 34-37.	1.8	44
29	Myeloablative conditioning for allo-HSCT in pediatric ALL: FTBI or chemotherapy? A multicenter EBMT-PDWP study. <i>Bone Marrow Transplantation</i> , 2020, 55, 1540-1551.	2.4	42
30	Allogeneic bone marrow transplantation versus chemotherapy in high-risk childhood acute lymphoblastic leukaemia in first remission. <i>British Journal of Haematology</i> , 1997, 96, 387-394.	2.5	37
31	Mononuclear cell collection in patients undergoing extra-corporeal photo-chemotherapy for acute and chronic graft-vs.-host-disease (GvHD): Comparison between COBE Spectra version 4.7 and 6.0 (AutoPBSC). <i>Journal of Clinical Apheresis</i> , 2002, 17, 65-71.	1.3	35
32	Hematopoietic stem cell transplantation for children with high-risk acute lymphoblastic leukemia in first complete remission: a report from the AIEOP registry. <i>Haematologica</i> , 2013, 98, 1273-1281.	3.5	30
33	Transplantation in Children and Adolescents with Acute Lymphoblastic Leukemia from a Matched Donor versus an HLA-Identical Sibling: Is the Outcome Comparable? Results from the International BFM ALL SCT 2007 Study. <i>Biology of Blood and Marrow Transplantation</i> , 2019, 25, 2197-2210.	2.0	30
34	COVID-19 in Immunosuppressed Children. <i>Frontiers in Pediatrics</i> , 2021, 9, 629240.	1.9	30
35	Mesenchymal Stromal Cells Do Not Increase the Risk of Viral Reactivation Nor the Severity of Viral Events in Recipients of Allogeneic Stem Cell Transplantation. <i>Stem Cells International</i> , 2012, 2012, 1-6.	2.5	28
36	Occurrence of long-term effects after hematopoietic stem cell transplantation in children affected by acute leukemia receiving either busulfan or total body irradiation: results of an AIEOP (Associazione Italiana Ematologia Oncologia Pediatrica) retrospective study. <i>Bone Marrow Transplantation</i> , 2020, 55, 1918-1927.	2.4	28

#	ARTICLE	IF	CITATIONS
37	Congenital erythrocytosis associated with gain-of-function HIF2A gene mutations and erythropoietin levels in the normal range. <i>Haematologica</i> , 2013, 98, 1624-1632.	3.5	27
38	Allogeneic Stem Cell Transplantation from HLA-Mismatched Donors for Pediatric Patients with Acute Lymphoblastic Leukemia Treated According to the 2003 BFM and 2007 International BFM Studies: Impact of Disease Risk on Outcomes. <i>Biology of Blood and Marrow Transplantation</i> , 2018, 24, 1848-1855.	2.0	27
39	Eligibility for allogeneic transplantation in very high risk childhood acute lymphoblastic leukemia: the impact of the waiting time. <i>Haematologica</i> , 2008, 93, 925-929.	3.5	23
40	Supportive care during pediatric hematopoietic stem cell transplantation: beyond infectious diseases. A report from workshops on supportive care of the Pediatric Diseases Working Party (PDWP) of the European Society for Blood and Marrow Transplantation (EBMT). <i>Bone Marrow Transplantation</i> , 2020, 55, 1126-1136.	2.4	23
41	Treatment and Outcome Analysis of 639 Relapsed Non-Hodgkin Lymphomas in Children and Adolescents and Resulting Treatment Recommendations. <i>Cancers</i> , 2021, 13, 2075.	3.7	23
42	High-dose vincristine, fractionated total-body irradiation and cyclophosphamide as conditioning regimen in allogeneic and autologous bone marrow transplantation for childhood acute lymphoblastic leukaemia in second remission: a 7-year Italian multicentre study. <i>British Journal of Haematology</i> , 1995, 89, 790-797.	2.5	22
43	Supportive Care During Pediatric Hematopoietic Stem Cell Transplantation: Prevention of Infections. A Report From Workshops on Supportive Care of the Paediatric Diseases Working Party (PDWP) of the European Society for Blood and Marrow Transplantation (EBMT). <i>Frontiers in Pediatrics</i> , 2021, 9, 705179.	1.9	22
44	Tisagenlecleucel in pediatric and young adult patients with Down syndrome-associated relapsed/refractory acute lymphoblastic leukemia. <i>Leukemia</i> , 2022, 36, 1508-1515.	7.2	21
45	Molecular remission induced by gemtuzumab ozogamicin associated with donor lymphocyte infusions in t(4;11) acute lymphoblastic leukemia relapsed after transplantation. <i>Leukemia</i> , 2003, 17, 2247-2248.	7.2	20
46	Allogeneic Hematopoietic Stem Cell Transplantation for Philadelphia-Positive Acute Lymphoblastic Leukemia in Children and Adolescents: A Retrospective Multicenter Study of the Italian Association of Pediatric Hematology and Oncology (AIEOP). <i>Biology of Blood and Marrow Transplantation</i> , 2012, 18, 852-860.	2.0	18
47	The role of hematopoietic stem cell transplantation for sickle cell disease in the era of targeted disease-modifying therapies and gene editing. <i>Lancet Haematology</i> , 2020, 7, e902-e911.	4.6	18
48	Total Body Irradiation in Hematopoietic Stem Cell Transplantation for Paediatric Acute Lymphoblastic Leukaemia: Review of the Literature and Future Directions. <i>Frontiers in Pediatrics</i> , 2021, 9, 774348.	1.9	15
49	Reconstitution of lymphocyte subpopulations in children with inherited metabolic storage diseases after hematopoietic cell transplantation. <i>British Journal of Haematology</i> , 2005, 130, 249-255.	2.5	14
50	Late Effects After Hematopoietic Stem Cell Transplantation in ALL, Long-Term Follow-Up and Transition: A Step Into Adult Life. <i>Frontiers in Pediatrics</i> , 2021, 9, 773895.	1.9	14
51	Febrile Complications in the First 100 Days After Bone Marrow Transplantation in Children: A Single Center's Experience. <i>Pediatric Hematology and Oncology</i> , 1997, 14, 335-347.	0.8	12
52	CD34+ Stem Cell Recovery After Positive Selection of "Overloaded" Immunomagnetic Columns. <i>Stem Cells and Development</i> , 2005, 14, 740-743.	2.1	12
53	The impact of donor type on the outcome of pediatric patients with very high risk acute lymphoblastic leukemia. A study of the ALL SCT 2003 BFM-SG and 2007-BFM-International SG. <i>Bone Marrow Transplantation</i> , 2021, 56, 257-266.	2.4	11
54	Tisagenlecleucel (Tisa) for relapsed/refractory (r/r) acute lymphoblastic leukemia (ALL): B2001X study focusing on prior exposure to blinatumomab (BLINA) and inotuzumab (INO).. <i>Journal of Clinical Oncology</i> , 2020, 38, 10518-10518.	1.6	10

#	ARTICLE	IF	CITATIONS
55	COVID-19 Impact on Childhood Haematology Patients. HemaSphere, 2020, 4, e465.	2.7	9
56	Autologous purified peripheral blood stem cell transplantation compare to chemotherapy in childhood acute lymphoblastic leukemia after low-risk relapse. Pediatric Blood and Cancer, 2011, 57, 654-659.	1.5	7
57	Pentraxin 3 plasma levels at graft-versus-host disease onset predict disease severity and response to therapy in children given haematopoietic stem cell transplantation. Oncotarget, 2016, 7, 82123-82138.	1.8	6
58	Serum anti-Müllerian hormone as a marker of ovarian reserve after cancer treatment and/or hematopoietic stem cell transplantation in childhood: proposal for a systematic approach to gonadal assessment. European Journal of Endocrinology, 2021, 185, 717-728.	3.7	5
59	Acute Lymphoblastic Leukaemia in the Youngest: Haematopoietic Stem Cell Transplantation and Beyond. Frontiers in Pediatrics, 2022, 10, 807992.	1.9	5
60	Transplantation in Childhood Very High Risk Acute Lymphoblastic Leukemia in First Complete Remission: Where Are We Now?. Journal of Clinical Oncology, 2007, 25, 2625-2626.	1.6	4
61	Early (Day ~7) versus Conventional (Day ~1) Inception of Cyclosporine-A for Graft-versus-Host Disease Prophylaxis after Unrelated Donor Hematopoietic Stem Cell Transplantation in Children. Long-Term Results of an AIEOP Prospective, Randomized Study. Biology of Blood and Marrow Transplantation, 2009, 15, 741-748.	2.0	4
62	Two pregnancies shortly after transplantation with reduced intensity conditioning in chronic myeloid leukemia. Pediatric Transplantation, 2016, 20, 158-161.	1.0	4
63	The Value of Minimal Residual Disease (and Diamonds). Biology of Blood and Marrow Transplantation, 2017, 23, 3-5.	2.0	3
64	High <i>EVI1</i> Expression due to <i>NRIP1/EVI1</i> Fusion in Therapy-related Acute Myeloid Leukemia: Description of the First Pediatric Case. HemaSphere, 2020, 4, e471.	2.7	3
65	ABO incompatible graft management in pediatric transplantation. Bone Marrow Transplantation, 2021, 56, 84-90.	2.4	3
66	The Impact of a Precision-Based Exercise Intervention in Childhood Hematological Malignancies Evaluated by an Adapted Yo-Yo Intermittent Recovery Test. Cancers, 2022, 14, 1187.	3.7	3
67	Osteonecrosis in paediatric acute lymphoblastic leukaemia: Incidence, risk factors, radiological patterns and evolution in a single-centre cohort. British Journal of Haematology, 2022, , .	2.5	2
68	Immunological response after mild COVID-19: How long will it last?. EBioMedicine, 2021, 72, 103597.	6.1	1
69	Avascular necrosis of the talus in pediatric acute lymphoblastic leukemia: current concepts. Minerva Ortopedica E Traumatologica, 2019, 70, .	0.3	1
70	Osteopathic Treatment and Evaluation in the Clinical Setting of Childhood Hematological Malignancies. Cancers, 2021, 13, 6321.	3.7	1